| Symbol | CMMB |
|---|---|
| Name | CHEMOMAB THERAPEUTICS LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | KIRYAT ATIDIM,BUILDING 7, TEL AVIV, 6158002, Israel |
| Telephone | +972 773310156 |
| Fax | — |
| — | |
| Website | https://www.chemomab.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001534248 |
| Description | Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The companys lead candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions. Additional info from NASDAQ: |
New Form SCHEDULE 13D - Chemomab Therapeutics Ltd. <b>Filed:</b> 2026-07-16 <b>AccNo:</b> 0001104659-26-084244 <b>Size:</b> 129 KB
Read moreChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Read moreChemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Read moreNew Form 3 - Chemomab Therapeutics Ltd. <b>Filed:</b> 2026-06-03 <b>AccNo:</b> 0001178913-26-003083 <b>Size:</b> 4 KB
Read moreDirector Mor George Adi 🔴 sold 60.3K shares of Chemomab Therapeutics Ltd. (CMMB) at $2.08 Transaction Date: May 29, 2026 | Filing ID: 003004
Read moreChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Read moreChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form 3 - Chemomab Therapeutics Ltd. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001178913-26-002068 <b>Size:</b> 13 KB
Read moreNew Form 3 - Chemomab Therapeutics Ltd. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001178913-26-002066 <b>Size:</b> 13 KB
Read moreNew Form 3 - Chemomab Therapeutics Ltd. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001178913-26-002062 <b>Size:</b> 10 KB
Read more